PE20081314A1 - COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB - Google Patents
COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kBInfo
- Publication number
- PE20081314A1 PE20081314A1 PE2007001067A PE2007001067A PE20081314A1 PE 20081314 A1 PE20081314 A1 PE 20081314A1 PE 2007001067 A PE2007001067 A PE 2007001067A PE 2007001067 A PE2007001067 A PE 2007001067A PE 20081314 A1 PE20081314 A1 PE 20081314A1
- Authority
- PE
- Peru
- Prior art keywords
- steroidal
- modulators
- activity
- independently
- glucocorticoid receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES DE FORMULA (I) EN DONDE Z ES HETEROCICLICO, HETEROARILO Y CIANO; A ES CARBOCICLICO O HETEROCICLICO DE 5 A 8 MIEMBROS; B ES CICLOALQUILO, ARILO, HETEROARILO, ENTRE OTROS; J1, J2 Y J3 SON INDEPENDIENTEMENTE -A1QA2-; Q ES O, S, S(O), S(O)2; A1 Y A2 SON INDEPENDIENTEMENTE ENLACE, ALQUILENO(C1-C3), ALQUENILENO(C2-C4), ENTRE OTROS; R1, R2, R3, R4, R5, R6, R7 Y R8 SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO, ENTRE OTROS; R9 Y R10 SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO, ENTRE OTROS; R11 ES H, ALQUILO, AMINO, ENTRE OTROS. SON SELECCIONADOS DE: N-{4-[4-(4-PIRIDINIL) BENCIL]-1,3-TIAZOL-2-IL}-2-(9H-XANTEN-9-IL) ACETAMIDA, N-[4-(4-FLUORO-1-NAFTIL)-1,3-TIAZOL-2-IL]-2-(9H-XANTEN-9-IL) ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB, SIENDO UTILES EN EL TRATAMIENTO DE INFLAMACION O INMUNES, OBESIDAD Y DIABETES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83649606P | 2006-08-09 | 2006-08-09 | |
US11/835,438 US8034940B2 (en) | 2006-08-09 | 2007-08-08 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081314A1 true PE20081314A1 (es) | 2008-10-17 |
Family
ID=39052386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001067A PE20081314A1 (es) | 2006-08-09 | 2007-08-09 | COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB |
Country Status (17)
Country | Link |
---|---|
US (1) | US8034940B2 (es) |
EP (1) | EP2049507A2 (es) |
JP (1) | JP2010500376A (es) |
KR (1) | KR20090038930A (es) |
CN (1) | CN101528718B (es) |
AR (1) | AR062312A1 (es) |
AU (1) | AU2007286221A1 (es) |
BR (1) | BRPI0716641A2 (es) |
CA (1) | CA2660318A1 (es) |
CL (1) | CL2007002330A1 (es) |
EA (1) | EA200900291A1 (es) |
IL (1) | IL196814A0 (es) |
MX (1) | MX2009001220A (es) |
NO (1) | NO20090564L (es) |
PE (1) | PE20081314A1 (es) |
TW (1) | TW200815454A (es) |
WO (1) | WO2008021926A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用 |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
CN101573356A (zh) | 2006-11-01 | 2009-11-04 | 百时美施贵宝公司 | 糖皮质激素受体、AP-1和/或NF-kB活性的调节剂及其用途 |
EP2094692B1 (en) | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
EP2247597A1 (en) * | 2008-02-07 | 2010-11-10 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
TW201000107A (en) * | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
WO2009152102A2 (en) * | 2008-06-10 | 2009-12-17 | The Regents Of The University Of California | Pro-fluorescent probes |
WO2009158380A1 (en) * | 2008-06-24 | 2009-12-30 | Bristol-Myers Squibb Company | Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof |
JPWO2010001990A1 (ja) | 2008-07-03 | 2011-12-22 | 協和発酵キリン株式会社 | 四環系化合物 |
WO2011081173A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 四環系化合物 |
EP2524057B1 (en) * | 2010-01-15 | 2016-03-30 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
WO2015027015A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imidazole-derived modulators of the glucocorticoid receptor |
US9593113B2 (en) * | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
WO2016123244A1 (en) * | 2015-01-27 | 2016-08-04 | Indicator Systems International, Inc. | Fluorescein polymer conjugates |
WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
CA3092362A1 (en) * | 2017-10-19 | 2019-04-25 | Tempest Therapeutics, Inc. | Picolinamide compounds |
CN113862704B (zh) * | 2021-11-15 | 2023-07-21 | 南昌航空大学 | 一种9-芳基呫吨类化合物的制备方法 |
AR127618A1 (es) | 2021-11-29 | 2024-02-14 | Bayer Ag | Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
EP0636619A1 (en) | 1991-09-13 | 1995-02-01 | Sankyo Company Limited | Tricyclic heterocyclic compound |
US5453421A (en) | 1992-09-11 | 1995-09-26 | E. R. Squibb & Sons, Inc. | Aryl and heterocyclic substituted propenamide derivatives |
TW306916B (es) | 1994-09-13 | 1997-06-01 | Ciba Geigy Ag | |
DE19610882A1 (de) | 1996-03-20 | 1997-09-25 | Dresden Arzneimittel | Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO1998015546A1 (en) | 1996-10-04 | 1998-04-16 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
CA2251580A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
ZA9811898B (en) | 1997-12-29 | 2000-06-28 | Ortho Mcneil Pharm Inc | Anti-Inflammatory Compounds. |
EP1183229B1 (en) | 1999-05-17 | 2005-10-26 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
JP2005518371A (ja) | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
US7482344B2 (en) | 2003-12-19 | 2009-01-27 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
CN1918151A (zh) | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
EP1828144A2 (en) | 2004-11-12 | 2007-09-05 | OSI Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
JP4943826B2 (ja) | 2005-11-25 | 2012-05-30 | 田辺三菱製薬株式会社 | 医薬組成物 |
CN101573356A (zh) | 2006-11-01 | 2009-11-04 | 百时美施贵宝公司 | 糖皮质激素受体、AP-1和/或NF-kB活性的调节剂及其用途 |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用 |
EP2094692B1 (en) | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
-
2007
- 2007-08-08 US US11/835,438 patent/US8034940B2/en active Active
- 2007-08-09 AU AU2007286221A patent/AU2007286221A1/en not_active Abandoned
- 2007-08-09 EP EP07800057A patent/EP2049507A2/en not_active Withdrawn
- 2007-08-09 CN CN200780037118XA patent/CN101528718B/zh not_active Expired - Fee Related
- 2007-08-09 WO PCT/US2007/075543 patent/WO2008021926A2/en active Application Filing
- 2007-08-09 KR KR1020097004788A patent/KR20090038930A/ko not_active Application Discontinuation
- 2007-08-09 BR BRPI0716641-9A patent/BRPI0716641A2/pt not_active Application Discontinuation
- 2007-08-09 CL CL200702330A patent/CL2007002330A1/es unknown
- 2007-08-09 EA EA200900291A patent/EA200900291A1/ru unknown
- 2007-08-09 AR ARP070103536A patent/AR062312A1/es not_active Application Discontinuation
- 2007-08-09 PE PE2007001067A patent/PE20081314A1/es not_active Application Discontinuation
- 2007-08-09 JP JP2009523988A patent/JP2010500376A/ja not_active Withdrawn
- 2007-08-09 MX MX2009001220A patent/MX2009001220A/es not_active Application Discontinuation
- 2007-08-09 TW TW096129426A patent/TW200815454A/zh unknown
- 2007-08-09 CA CA002660318A patent/CA2660318A1/en not_active Abandoned
-
2009
- 2009-02-01 IL IL196814A patent/IL196814A0/en unknown
- 2009-02-05 NO NO20090564A patent/NO20090564L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2008021926A3 (en) | 2008-05-22 |
EP2049507A2 (en) | 2009-04-22 |
JP2010500376A (ja) | 2010-01-07 |
CA2660318A1 (en) | 2008-02-21 |
KR20090038930A (ko) | 2009-04-21 |
BRPI0716641A2 (pt) | 2013-10-15 |
WO2008021926A2 (en) | 2008-02-21 |
CN101528718A (zh) | 2009-09-09 |
TW200815454A (en) | 2008-04-01 |
MX2009001220A (es) | 2009-02-11 |
US8034940B2 (en) | 2011-10-11 |
EA200900291A1 (ru) | 2009-10-30 |
US20090075995A1 (en) | 2009-03-19 |
NO20090564L (no) | 2009-03-19 |
AU2007286221A1 (en) | 2008-02-21 |
CN101528718B (zh) | 2011-11-09 |
AR062312A1 (es) | 2008-10-29 |
IL196814A0 (en) | 2009-11-18 |
CL2007002330A1 (es) | 2008-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081314A1 (es) | COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
PE20070528A1 (es) | Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
RU2006146070A (ru) | Циннамидное соединение | |
PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
PE20090482A1 (es) | Derivados heterociclicos como antagonistas del receptor ccr2 | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
AR054799A1 (es) | Derivados de oxindol | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
PE20060273A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 | |
PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |